Abstract: Tofacitinib is a commonly used JAK inhibitor, which is approved in China for the treatment of moderate to severe rheumatoid arthritis and ankylosing spondylitis. Although the use of tofacitinib in dermatology is still off-label, an increasing number of studies have shown its therapeutic effects on various skin diseases such as psoriasis, alopecia areata, vitiligo, and autoimmune bullous diseases. The mechanism of action, efficacy and safety of tofacitinib in the treatment of skin diseases is reviewed in this paper to provide reference for clinical treatment.

Key words: tofacitinib, JAK inhibitor, treatment